Why Guardant Health is on investors’ radar

Guardant Health (GH) is drawing attention after recent share price moves, with the stock showing a mix of short term fluctuations and stronger longer term returns that have some investors reassessing the precision oncology specialist.

The recent 3.2% 1 day share price return and 12.1% year to date share price return to US$114.04 sit alongside a 1 year total shareholder return of 142.7% and a 3 year total shareholder return above 2.5x. Together, these figures point to momentum that has attracted fresh attention to Guardant Health despite a weaker 5 year total shareholder return.

If Guardant Health has you looking closer at precision oncology, it could be a good time to cast a wider net across healthcare stocks as you compare ideas.

With the share price rallying and recent returns looking strong, the key question now is whether Guardant Health’s valuation still leaves a margin of safety or if the market is already pricing in much of its potential growth.

Most Popular Narrative: 5.9% Undervalued

Guardant Health’s most followed narrative sets a fair value of about $121.19 per share, a touch above the recent $114.04 close, framing the stock as modestly undervalued on long term assumptions.

Rapid integration of AI-powered clinical analytics and multi-omic profiling into Guardant's "Smart Liquid Biopsy" platform is creating new clinical applications, enhancing product utility and differentiation versus peers, which is leading to higher average selling prices (ASPs), rising margins, and increased potential for broader payer reimbursement and improved net margins.

Curious what kind of growth path and margin shift that quote implies? The narrative leans on ambitious revenue compounding, margin uplift, and a rich future earnings multiple. The detailed assumptions sit behind that 5.9% discount and a fair value that edges above today’s price.

Result: Fair Value of $121.19 (UNDERVALUED)

However, that upside story depends on heavy spending eventually easing and on broader payer coverage for Shield, so any setback on costs or reimbursement could quickly challenge the outlook.

Another view: pricing looks far less forgiving

While the narrative and cash flow work suggest Guardant Health is undervalued, its current P/S of 16.3x is sharply higher than the US Healthcare average of 1.2x and a fair ratio of 6.6x. That gap points to rich expectations, so which signal do you trust more?

Build Your Own Guardant Health Narrative

If that does not quite match your view, or you prefer to work directly from the numbers, you can test your own thesis in minutes using Do it your way.

A great starting point for your Guardant Health research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Guardant Health has your attention, do not stop there. Use the same tools to scout fresh ideas that fit your style before the crowd does.

• Target potential mispricings by scanning these 875 undervalued stocks based on cash flows that may offer more attractive entry points based on their cash flow profiles.
• Ride major tech shifts by zeroing in on these 24 AI penny stocks that are building businesses around artificial intelligence.
• Tap into high income ideas by checking out these 12 dividend stocks with yields > 3% that deliver yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.